[ 223 Ra] RaCl 2 nanomicelles showed potent effect against osteosarcoma: targeted alpha therapy in the nanotechnology era.

The treatment of bone metastatsis as primary bone cancer itself is still a challenge. The use od radium dichloride ([ 223 Ra] RaCl 2 ) has emerged in the last few years as one of the best treatment choice for bone cancer, with especial focus in bone metastasis. The alpha-emitter radiopharmaceutical has showed potent and efficient results in several clinical trials. In this study we have formulated radium dichloride ([ 223 Ra] RaCl 2 ) nanomicelles in order to evaluate and compare with pure radium dichloride ([ 223 Ra] RaCl 2 ). The results showed that nanomicelles at the same dose had a superior effect (20% higher efficient) when compared with pure radium dichloride ([ 223 Ra] RaCl 2 ). The results corroborated the effectiveness of the nanosystem validating the application of nanotechnology in alpha-radiotherapy with radium dichloride ([ 223 Ra] RaCl 2 ).